Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation

Alan BoobisDepartment of Medicine, Imperial College London, London, UK;

Paul BrownUS Food and Drug Administration, Silver Spring, MD, USA;

Mark Timothy David CroninSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK;

James EdwardsDSM Nutritional Products Ltd, Kaiseraugst, Switzerland;

Corrado Lodovico GalliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy;

Jay GoodmanDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA;

Abigail JacobsUS Food and Drug Administration, Silver Spring, MD, USA;

David KirklandKirkland Consulting, Tadcaster, UK;

Mirjam LuijtenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands;

Cyril MarsauxILSI Europe a.i.s.b.l., Brussels, Belgium; Correspondence[email protected]

Matthew MartinEnvironmental Protection Agency, Washington, DC, USA;

Chihae YangChemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA; ;Molecular Networks GmbH, Nürnberg, Germany; ;Altamira LLC, Columbus, OH, USA;

Heli Miriam HollnagelDow Europe GmbH, Horgen, Switzerland

show all

Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date